Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

BACKGROUND: Cavity occurs in 5.7 to 14.9% of patients with lung adenocarcinoma (ADC). However, the impact of cavity on the therapeutic response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in ADC patients with EGFR mutations remains unclear. The aim of the present retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Fei, Ma, Wanrong, Li, Wei, Ni, Huijuan, Gao, Guanghui, Chen, Xiaoxia, Zhang, Jie, Shi, Jingyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199793/
https://www.ncbi.nlm.nih.gov/pubmed/30352571
http://dx.doi.org/10.1186/s12885-018-4938-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199793/
https://www.ncbi.nlm.nih.gov/pubmed/30352571
http://dx.doi.org/10.1186/s12885-018-4938-9

Ejemplares similares